These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 38479721)
41. Activation of the p62-Keap1-Nrf2 pathway improves pulmonary arterial hypertension in MCT-induced rats by inhibiting autophagy. Jiang G; Shi LF; Li LJ; Duan XJ; Zheng ZF FASEB J; 2024 Feb; 38(3):e23452. PubMed ID: 38308640 [TBL] [Abstract][Full Text] [Related]
42. A modified Fangji Huangqi decoction ameliorates pulmonary artery hypertension via phosphatidylinositide 3-kinases/protein kinase B-mediated regulation of proliferation and apoptosis of smooth muscle cells in vitro and in vivo. Xue Z; Zhou M; Liu Y; Qin H; Li Y; Zhu Y; Yang J J Ethnopharmacol; 2023 Oct; 314():116544. PubMed ID: 37088239 [TBL] [Abstract][Full Text] [Related]
43. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats. Cheng Y; Yu M; Xu J; He M; Wang H; Kong H; Xie W BMC Pulm Med; 2018 Aug; 18(1):130. PubMed ID: 30086741 [TBL] [Abstract][Full Text] [Related]
44. Bioactive Compounds From Coptidis Rhizoma Alleviate Pulmonary Arterial Hypertension by Inhibiting Pulmonary Artery Smooth Muscle Cells' Proliferation and Migration. Luo S; Kan J; Zhang J; Ye P; Wang D; Jiang X; Li M; Zhu L; Gu Y J Cardiovasc Pharmacol; 2021 Aug; 78(2):253-262. PubMed ID: 34554677 [TBL] [Abstract][Full Text] [Related]
45. Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension. Kurosawa R; Satoh K; Kikuchi N; Kikuchi H; Saigusa D; Al-Mamun ME; Siddique MAH; Omura J; Satoh T; Sunamura S; Nogi M; Numano K; Miyata S; Uruno A; Kano K; Matsumoto Y; Doi T; Aoki J; Oshima Y; Yamamoto M; Shimokawa H Circ Res; 2019 Jul; 125(3):309-327. PubMed ID: 31195886 [TBL] [Abstract][Full Text] [Related]
47. Prostanoid EP Li HH; Hsu HH; Chang GJ; Chen IC; Ho WJ; Hsu PC; Chen WJ; Pang JS; Huang CC; Lai YJ Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L349-L359. PubMed ID: 29146573 [TBL] [Abstract][Full Text] [Related]
48. Interferon regulatory factor 7 inhibits rat vascular smooth muscle cell proliferation and inflammation in monocrotaline-induced pulmonary hypertension. Deng Y; Guo SL; Li JQ; Xie SS; Zhou YC; Wei B; Wang Q; Wang F Life Sci; 2021 Jan; 264():118709. PubMed ID: 33152351 [TBL] [Abstract][Full Text] [Related]
49. Inhibition of HDAC1 alleviates monocrotaline-induced pulmonary arterial remodeling through up-regulation of miR-34a. Li F; Wang D; Wang H; Chen L; Sun X; Wan Y Respir Res; 2021 Aug; 22(1):239. PubMed ID: 34465322 [TBL] [Abstract][Full Text] [Related]
50. Isorhynchophylline protects against pulmonary arterial hypertension and suppresses PASMCs proliferation. Guo H; Zhang X; Cui Y; Deng W; Xu D; Han H; Wang H; Chen Y; Li Y; Wu D Biochem Biophys Res Commun; 2014 Jul; 450(1):729-34. PubMed ID: 24950404 [TBL] [Abstract][Full Text] [Related]
51. CircItgb5 promotes synthetic phenotype of pulmonary artery smooth muscle cells via interacting with miR-96-5p and Uba1 in monocrotaline-induced pulmonary arterial hypertension. Su H; Zhu H; Wang S; Li Y; Yan C; Wang J; Ying K Respir Res; 2023 Jun; 24(1):165. PubMed ID: 37344798 [TBL] [Abstract][Full Text] [Related]
53. Dysregulation of miR-135a-5p promotes the development of rat pulmonary arterial hypertension in vivo and in vitro. Liu HM; Jia Y; Zhang YX; Yan J; Liao N; Li XH; Tang Y Acta Pharmacol Sin; 2019 Apr; 40(4):477-485. PubMed ID: 30038339 [TBL] [Abstract][Full Text] [Related]
54. The Anti-Inflammatory Effects and Clinical Potential of Dexmedetomidine in Pulmonary Arterial Hypertension. Yamaguchi Y; Hosokawa S; Haraguchi G; Kajikawa Y; Sakurai M; Ishii T; Ando N; Morio T; Doi S; Furukawa T J Pharmacol Exp Ther; 2023 May; 385(2):88-94. PubMed ID: 36849413 [TBL] [Abstract][Full Text] [Related]
55. Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension. Xi X; Liu S; Shi H; Yang M; Qi Y; Wang J; Du J Cardiovasc Toxicol; 2014 Dec; 14(4):368-78. PubMed ID: 24825325 [TBL] [Abstract][Full Text] [Related]
56. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354. Hosokawa S; Haraguchi G; Sasaki A; Arai H; Muto S; Itai A; Doi S; Mizutani S; Isobe M Cardiovasc Res; 2013 Jul; 99(1):35-43. PubMed ID: 23631839 [TBL] [Abstract][Full Text] [Related]
57. Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension. Vitry G; Paulin R; Grobs Y; Lampron MC; Shimauchi T; Lemay SE; Tremblay E; Habbout K; Awada C; Bourgeois A; Nadeau V; Paradis R; Breuils-Bonnet S; Roux-Dalvai F; Orcholski M; Potus F; Provencher S; Boucherat O; Bonnet S Am J Respir Crit Care Med; 2021 Mar; 203(5):614-627. PubMed ID: 33021405 [No Abstract] [Full Text] [Related]
58. Formononetin attenuates monocrotaline‑induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats. Cai C; Xiang Y; Wu Y; Zhu N; Zhao H; Xu J; Lin W; Zeng C Mol Med Rep; 2019 Dec; 20(6):4984-4992. PubMed ID: 31702810 [TBL] [Abstract][Full Text] [Related]
59. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442 [TBL] [Abstract][Full Text] [Related]
60. Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension via PI3K/Akt and ERK signaling. Zhang S; Wang J; Qi X; Tao X; Xie W; Wan J; Shen YH; Zhai Z Exp Cell Res; 2021 Jan; 398(1):112392. PubMed ID: 33227315 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]